IS8277A - Blanda af serótónín endurupptöku hindra og glysínflutningsprótín gerð I hindra við meðferð á þunglyndi - Google Patents

Blanda af serótónín endurupptöku hindra og glysínflutningsprótín gerð I hindra við meðferð á þunglyndi

Info

Publication number
IS8277A
IS8277A IS8277A IS8277A IS8277A IS 8277 A IS8277 A IS 8277A IS 8277 A IS8277 A IS 8277A IS 8277 A IS8277 A IS 8277A IS 8277 A IS8277 A IS 8277A
Authority
IS
Iceland
Prior art keywords
inhibitor
depression
mixture
treatment
serotonin reuptake
Prior art date
Application number
IS8277A
Other languages
English (en)
Inventor
Didriksen Michael
Hogg Willigers Sandra
Arnt Jørn
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of IS8277A publication Critical patent/IS8277A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS8277A 2003-08-21 2006-01-31 Blanda af serótónín endurupptöku hindra og glysínflutningsprótín gerð I hindra við meðferð á þunglyndi IS8277A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49673803P 2003-08-21 2003-08-21
DKPA200301198 2003-08-21
PCT/DK2004/000547 WO2005018676A1 (en) 2003-08-21 2004-08-18 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression

Publications (1)

Publication Number Publication Date
IS8277A true IS8277A (is) 2006-01-31

Family

ID=34219531

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8277A IS8277A (is) 2003-08-21 2006-01-31 Blanda af serótónín endurupptöku hindra og glysínflutningsprótín gerð I hindra við meðferð á þunglyndi

Country Status (12)

Country Link
US (1) US20060223857A1 (is)
EP (1) EP1660130A1 (is)
JP (1) JP2007502785A (is)
KR (1) KR20060066729A (is)
CN (1) CN1867358A (is)
AU (1) AU2004266057A1 (is)
BR (1) BRPI0413587A (is)
CA (1) CA2536275A1 (is)
IS (1) IS8277A (is)
MX (1) MXPA06002002A (is)
NO (1) NO20061167L (is)
WO (1) WO2005018676A1 (is)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100457738C (zh) * 2001-12-20 2009-02-04 H·隆德贝克有限公司 芳氧基苯基和芳硫基苯基衍生物
US8604080B2 (en) * 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
CN101338337B (zh) * 2007-07-04 2011-11-02 北京华安佛医药研究中心有限公司 多态性位点基因型预测抑郁症及药效的用途、方法和试剂盒
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000501707A (ja) * 1995-12-07 2000-02-15 ジャビット，ダニエル・シー グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
CZ294348B6 (cs) * 1996-05-31 2004-12-15 Allelix Neuroscience Inc. Substituovaný derivát glycinu a farmaceutický prostředek s jeho obsahem
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
DOP2001000189A (es) * 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
CZ2003396A3 (cs) * 2000-07-21 2003-05-14 H. Lundbeck A/S Inhibitory transportu glycinu
CN100457738C (zh) * 2001-12-20 2009-02-04 H·隆德贝克有限公司 芳氧基苯基和芳硫基苯基衍生物
US20050288355A1 (en) * 2002-06-20 2005-12-29 Arne Mork Combination therapy wherein a serotonin reuptake inhibitor is used
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.

Also Published As

Publication number Publication date
WO2005018676A1 (en) 2005-03-03
NO20061167L (no) 2006-03-13
CA2536275A1 (en) 2005-03-03
CN1867358A (zh) 2006-11-22
MXPA06002002A (es) 2006-05-17
BRPI0413587A (pt) 2006-10-17
US20060223857A1 (en) 2006-10-05
JP2007502785A (ja) 2007-02-15
AU2004266057A1 (en) 2005-03-03
EP1660130A1 (en) 2006-05-31
KR20060066729A (ko) 2006-06-16

Similar Documents

Publication Publication Date Title
NO20043564L (no) Follistatindomene som inneholder proteiner
EP1636250A4 (en) SELF-ORGANIZING PEPTIDES CONTAINING MODIFICATIONS AND METHOD FOR THEIR USE
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
IL228034A0 (en) Formulations with a high concentration of antibodies and proteins
EP1495128A4 (en) IMPROVED PROTEIN EXPRESSION IN BACILLUS
IL171109A (en) Glycopegylation methods and proteins/peptides produced by the methods
NO20055306D0 (no) GITR ligand og GITR ligand relaterte molekyler og antistoffer og anvendelse derav
EP1732581A4 (en) POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES
DK1268431T3 (da) 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer
SI1641823T1 (sl) Fuzijski proteini analogni glp-1
EP1701725A4 (en) PROCESS AND COMPOSITIONS
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
DK1663291T3 (da) Rekombinante lubricinmolekyler og anvendelser deraf
DK1736541T3 (da) Nyt modificeret galectin 9-protein og anvendelse heraf
NO20055708D0 (no) Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav
IS8308A (is) Amínósýrur með sækni fyrir a2o prótíninu
IS8489A (is) Umritunarstillar og aðferðir þeirra
EP1734983A4 (en) MODIFIED ANNEXINE PROTEINS AND METHODS FOR PREVENTING THROMBOSIS
IS7962A (is) Þíenópýridasínón og notkun þeirra í breytingu á sjálfsnæmissjúkdómi
IS8326A (is) Blandan af serótónín endurupptöku hindra og loxapíni
FI20040655L (fi) Proteiini- ja peptidistabilointi
NO20055668D0 (no) Beta-amyloidinhibitorer og anvendelse derav
FI20030315A0 (fi) Menetelmiä ja konstruktioita valikoitujen aminohappojen pitoisuuksien lisäämiseksi siemenissä
NO20024029L (no) Nytt protein og gen som koder for proteinet
ES1052162Y (es) Contenedor para ostricultura y similares.